EARLY DIAGNOSIS AND PREVENTIVE STRATEGIES IN CANINE AND FELINE CARDIOLOGY

Cardiovascular disease is a significant cause of morbidity and mortality in companion animals, often progressing silently until clinical signs become apparent. For veterinary practitioners, early detection and preventive management remain critical to improving both longevity and quality of life in dogs and cats. Increasingly, this approach integrates not only traditional diagnostics and pharmacological interventions but also targeted nutritional and nutraceutical strategies.

The Importance of Early Diagnosis

Many cardiac conditions in pets—such as degenerative mitral valve disease (DMVD) in dogs or hypertrophic cardiomyopathy (HCM) in cats—develop gradually and may remain asymptomatic for extended periods. By the time overt clinical signs such as coughing, exercise intolerance, or dyspnoea appear, structural and functional cardiac changes are often advanced.

Routine clinical examinations play a pivotal role in early detection. Auscultation remains a simple yet effective screening tool, with heart murmurs often representing the first detectable abnormality. However, further diagnostic workup—including echocardiography, thoracic radiography, electrocardiography, and biomarkers such as NT-proBNP—enables staging and more accurate prognostication.

Early diagnosis allows:

• Timely initiation of therapy where indicated

• Monitoring of disease progression

• Implementation of lifestyle and nutritional interventions

• Improved client education and compliance

Age as a Key Risk Factor

Age is one of the most consistent predictors of cardiac disease in pets.

Dogs: The prevalence of DMVD increases significantly in middle-aged to senior dogs, particularly beyond 7–8 years of age.

Cats: While HCM can occur at any age, it is most commonly diagnosed in adult to senior cats, often between 5 and 10 years.

Geriatric patients should therefore be considered high priority for routine cardiovascular screening, even in the absence of clinical signs.

Breed Predisposition and Genetic Considerations

Breed-associated risk is a well-established factor in veterinary cardiology and should inform both screening protocols and client communication.

• Small-breed dogs (e.g., Cavalier King Charles Spaniels, Dachshunds): Predisposed to DMVD, often with earlier onset and faster progression in certain lines.

• Large and giant breeds (e.g., Doberman Pinschers, Boxers, Great Danes): Higher incidence of dilated cardiomyopathy (DCM), sometimes with a genetic component.

• Cats: Breeds such as Maine Coons, Ragdolls, and British Shorthairs have documented predispositions to HCM, often linked to heritable mutations.

Recognising these predispositions allows for proactive screening strategies, including earlier and more frequent cardiac evaluations.

Preventive Management: Beyond Pharmacology

Preventive cardiology in veterinary medicine is not limited to early detection—it also encompasses interventions aimed at slowing disease progression and supporting overall cardiac health.

Key strategies include:

• Weight management and maintaining optimal body condition

• Controlled exercise tailored to the patient’s condition

• Monitoring and managing concurrent diseases (e.g., renal disease, hypertension, endocrine disorders)

• Nutritional optimisation

  
  

Within this framework, nutraceuticals have gained attention as a supportive tool in both preclinical and clinical stages of heart disease.

The Role of Nutraceuticals in Cardiac Support

Nutraceuticals can contribute to cardiac health by addressing several underlying mechanisms involved in disease progression, including oxidative stress, inflammation, and impaired myocardial energy metabolism.

Commonly utilised components include:

• Omega-3 fatty acids (EPA/DHA): Support anti-inflammatory pathways and may help mitigate cardiac cachexia.

• Taurine: Particularly critical in feline cardiac health and certain canine DCM cases.

• L-carnitine: Enhances fatty acid metabolism within cardiac muscle cells.

• Coenzyme Q10: Supports mitochondrial function and acts as an antioxidant.

• Antioxidants (e.g., Vitamin E, Selenium): Help reduce oxidative damage to cardiac tissues.

Integrating Nutraceuticals into Clinical Practice

Incorporating nutraceuticals into a cardiac management plan may be beneficial in several contexts:

• At-risk patients (e.g., predisposed breeds before clinical disease onset)

• Early-stage disease where structural changes are present but clinical signs are minimal

• Chronic management alongside standard pharmacological therapy

Cardiak Care and its unique formulation includes omega-3 fatty acids, taurine, L-carnitine, and antioxidants, aiming to provide a synergistic effect on cardiac metabolism and oxidative balance. For instance, these ingredients have been associated with supporting myocardial energy utilisation, maintaining body condition, and protecting against free radical damage.

From a clinical perspective, the value of these products lies less in any single ingredient and more in the combined targeting of multiple disease pathways.

Client Communication and Compliance

Preventive cardiology relies heavily on client engagement. Educating pet owners about breed risks, the importance of routine check-ups, and the value of early intervention is essential. Nutraceuticals can also play a role in improving owner perception of proactive care, particularly when introduced as part of a broader, veterinarian-led strategy.

Conclusion

Early diagnosis and prevention of heart disease in dogs and cats require a multifaceted approach that integrates risk assessment, routine screening, and comprehensive management strategies. Age and breed predisposition remain key determinants of risk, guiding both clinical vigilance and preventive care.

Nutraceuticals offer a promising adjunct in supporting cardiac function and addressing underlying pathophysiological processes. When used judiciously and in combination with evidence-based veterinary care, they can contribute meaningfully to improved outcomes in companion animal cardiology.

Ultimately, the goal is not only to extend lifespan but to enhance the quality of life—an objective best achieved through early, informed, and proactive intervention.